Biology, classification and treatment of human mastocytosis

Wiener Klinische Wochenschrift

Volumn 108, Issue 13, 1996, Pages 385-397

  Valent, P ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

c kit; interferon; mast cell growth factor; mastocystosis; tryptase

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; GROWTH FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 3; KETOTIFEN;

BIOCHEMISTRY; BIOLOGY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; MAST CELL; MASTOCYTOSIS; MORPHOLOGY; PUVA; REVIEW;

CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, MAST-CELL; MAST CELLS; MAST-CELL SARCOMA; MASTOCYTOSIS; PROGNOSIS; URTICARIA PIGMENTOSA;

EID: 0029986256     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Adachi S, Tsujimura T, Jippo T, Morimoto M, Isozaki K, Kasugai T, Nomura S, Kitamura Y (1995) Inhibition of attachment between cultured mast cells and fibroblasts by phorbol 12-myristate 13-acetate and stem cell factor. Exp Hematol 23: 58-65
2. Agis H, Bankl HC, Sillaber C, Baghestanian M, Kiener H, Graninger W, Sperr WR, Lechner K, Valent P: Bio chemical and phenotypic characterization of cells in patients with malignant mastocytosis. Concordant absence of skin mast cell markers and lack of skin infiltrates in human mast cell leukemia (submitted)
3. Agis H, Beil WJ, Bankl HC, Ghannadan M, Baghestanian M, Füreder W, Bettelheim P, Lechner K, Valent P (1996) Basophil- versus mast cell lineage involvement in myelodysplastic and leukemic disorders. Leukemia Lymphoma (in press)
4. Agis H, Willheim M, Kundi M, Füreder W, Bankl HC, Butterfield JH, Sperr WR, Kishi K, Lechner K, Valent P (1996) Comparative phenotypic analysis of human mast cells, blood monocytes and blood basophils: dissection of three distinct lineages. Immunology (in press)
5. -, colony forming cell. J Immunol 151: 4221-4227
6. Ashman LK, Cambareri AC, To LB, Levinski RJ, Juttner CA (1991) Expression of c-kit antigen (c-kit proto-oncogen product) by normal human bone marrow cells. Blood 78: 30-37
7. Bankl HC, Radaszkiewicz Th, Klappacher GW, Glogar D, Sperr WR, Großschmidt K, Bankl H, Lechner K, Valent P (1995) Increase and redistribution of mast cells in auricular thrombosis: possible role of kit ligand. Circulation 91: 275-283
8. Baghestanian M, Bankl HC, Sillaber C, Beil WJ, Radaszkiewicz T, Füreder W, Preiser J, Veselly M, Schernthaner G, Lechner K, Valent P (1996) A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. Leukemia 10: 159-166
9. Baghestanian M, Sillaber C, Bevec D, Füreder W, Agis H, Müller MR, Willheim M, Raidl M, Kapiotis S, Speiser W, Binder BR, Bettelheim P, Lechner K, Valent P (1994) Expression of pro-fibrinolytic activity, a high tPA/PAI ratio and uPAR/CD87 in human mast cells. Blood 84: 76a (abstr)
10. Benyon RC, Lowman MA, Church MK (1987) Human skin mast cells: Their dispersion, purification, and secretory characterization. J Immunol 138: 861-867
11. Beutler B, Cerami A (1988) Tumor necrosis, cachexia and inflammation: a common mediator. Ann Rev Biochem 57: 505-518
12. Bischoff SC, Dahinden CA (1992) c-kit Ligand: a unique potentiator of mediator release from human lung mast cells. J Exp Med 175: 237-244
13. Butterfield JH, Weiler D, Dewald G, Gleich GJ (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12: 345-355
14. Castells MC, Irani AMA, Schwartz LB (1987) Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 138: 2184-2189
15. Cohn MS, Mahon MJ (1994) Teleangiectasia macularis eruptiva perstans. J Am Osteopath Assoc 94: 246-248
16. Coser P, Quaglino D, De Pasquale A, Colombetti V, Prinoth O (1980) Cytobiological and clinical aspects of tissue mast cell leukemia. Br J Haematol 45: 5-12
17. Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark C, Crosier KE (1993) Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 82: 1151-1158
18. Dalton R, Chan L, Batten E, Eridani S (1986) Mast cell leukemia: evidence for bone marrow origin of the pathologic clone. Br J Hematol 64: 397-406
19. deCastro CM, Vandenbark GR, Gautier M, Kaufman RE (1992) PCR-SSCP analysis of the c-kit gene in patients with hematologic disorders. Blood 80: 412a (abstr)
20. Dubreuil P, Forrester L, Rottapel R, Reeduk M, Fujita J, Bernstein A (1991) The c-fms gene complements the mitogenic defect in mast cells derived from mutant W mice but not mi (microphthalmia) mice. Proc Natl Acad Sci (USA) 88: 2341-2345
21. Dvorak AM (1991) Basophil and mast cell degranulation and recovery. In: Harris JR (ed) Blood cell biochemistry. Plenum Press, New York, pp 1-370
22. Dvorak AM (1993) Human mast cells. Ultrastructural observations of in situ, ex vivo, and in vitro sites, sources and systems. In: Kaliner AM, Metcalfe DD (eds) The mast cell in health and diseases. Marcel Dekker, New York, pp 1-78
23. Dvorak AM, Schleimer RP, Lichtenstein LM (1988) Human mast cells synthesize new granules during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Blood 71: 76-85
24. Dvorak AM, Mitsui H, Ishizaka T (1993) Human and murine c-kit ligand support the development of human mast cells from umbilical cord blood cells: ultrastructural identification. Int Arch All Immunol 101: 247-253
25. Ehrlich P (1879) Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukozyten. Arch Anat Physiol 3: 166-169
26. Ellis JM (1949) Urticaria pigmentosa. A report of a case with autopsy. AMA Arch Pathol 48: 426-429
27. Födinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, Valent P, Mannhalter Ch (1994) Origin of human mast cells: development from transplanted hemopoietic stem cells after allogeneic bone marrow transplantation. Blood 84: 2954-2459
28. Friedman B, Darling G, Norton J, Hamby L, Metcalfe DD (1990) Splenectomy in the management of systemic mast cell disease. Surgery 107: 94-100
29. Füreder W, Agis H, Willheim M, Bankl HC, Maier U, Kishi K, Müller MR, Czerwenka K, Radaszkiewicz T, Butterfield JH, Klappacher G, Sperr WR, Oppermann M, Lechner K, Valent P (1995) Differential expression of complement receptors on human basophils and mast cells: evidence for mast cell heterogeneity and C5aR/CD88 expression on skin mast cells. J Immunol 155: 3152-3160
30. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 92: 1736-1744
31. Galli SJ (1993) New concepts about the mast cell. N Engl J Med 328: 257-265
32. Galli SJ (1990) Biology of disease: new insights into "the riddle of the mast cells": microenvironmentalk regulation of mast cell development and phenotypic heterogeneity. Lab Invest 62: 5-33
33. Goins VA (1991) Mastocytosis. Perioperative considerations. AORN-J 54: 1227-1238
34. Graves L, Stechschulte DJ, Morris DC, Luken BP (1994) Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Mineral Res 5: 1113-1119
35. Hansen U, Wiese R, Knolle J (1994) Shock and coagulation disorders in systemic mastocytosis. Dtsch Med Wochenschr 119: 1231-1234
36. Horan RF, Scheffer AL, Austen KF (1990) Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 85: 852-855
37. Horan RF, Austen KF (1991) Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 96: 5S-13S
38. Horny HP, Kaiserling E, Parwaresch MR, Lennert K (1992) Lymph node findings in generalized mastocytosis. Histopathology 21: 439-446
39. Horny HP, Schaumberg-Lever G, Bolz S, Geerts MI, Kaiserling E (1985) Bone marrow findings in systemic mastocytosis. Human Pathol 16: 808-814
40. Horny HP, Kaiserling E (1987) Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: a histological and immunohistological study. Br J Hematol 69: 449-455
41. Horny HP, Ruck M, Wehrmann M, Kaiserling E (1990) Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 76: 186-193
42. Horny HP, Ruck M, Kaiserling E (1992) Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer 70: 459-468
43. TC type. Clin Exp Allergy 20: 53-58
44. Irani AM, Nilsson G, Ashman LK, Schwartz LB (1995) Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology 84: 72-78
45. Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB (1992) Recombinant human stem cell factor stimulates differentiation of human mast cells from dispersed fetal liver cells. Blood 80: 3009-3016
46. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB (1986) Two human mast cell subsets with distinct neutral protease composition. Proc Natl Acad Sci (USA) 83: 4464-4468
47. Ishizaka T, Ishizaka K (1984) Activation of mast cells for mediator release through IgE receptors. Prog Allergy 34: 188-235
48. Johnstone PA, Mican JM, Metcalfe DD, DeLaney TF (1994) Radiotherapy or refractory bone pain due to systemic mast cell disease. Am J Clin Oncol 17: 328-330
49. + pluripotent progenitor cells. J Immunol 148: 772-777
50. + bone marrow progenitor cells. J Immunol 146: 1410-1415
51. i mice and their increase by bone marrow transplantation. Blood 52: 447-452
52. d mice. Blood 53: 492-497
53. d genotype. In: Galli SJ, Austen KF (eds) Mast cell and basophil differentiation and function in health and disease. Raven Press Ltd. New York, pp 12-15
54. Kimura A, Tanaka R, Taketomi Y, Dohi H, Fujimura K, Kamada N, Kuramoto A, Kajihara H, Aoki Y, Yamamoto S (1979) A case of mastocytoma with leukemic manifestation of its immature form in the terminal stage. Rinsho Ketsueki 20: 1137-1146
55. Kitamura Y, Yokoyama M, Matsuda H, Ohno T, Mori KJ (1981) Spleen colony forming cell as common precursor for tissue mast cells and granulocytes. Nature 291: 159-160
56. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R (1992) Response to inferferon alpha-2b in a patient with systemic mastocytosis. N Engl J Med 326: 619-623
57. Kots JW, van-Doormaal JJ, de-Monchy JG (1993) Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med 233: 255-258
58. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR (1991) Hematologic manifestation of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 91: 612-624
59. Lawrence ID, Warner JA. Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM (1987) Purification and characterization of human skin mast cells. J Immunol 139: 3062-3069
60. Lennert K, Parwaresch MR (1979) Mast cells and mast cell neoplasia: a review. Histopathology 3: 349-365
61. Lewis JP, Welborn JL, Meyers FJ, Levy NB, Roschak T (1987) Mast cell disease followed by leukemia with clonal evolution. Leuk Res 11: 769-773
62. Longley BJ, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R (1993) Altered metabolism of mast cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 328: 1302-1307
63. Metcalfe DD (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96: 2S-4S
64. Metcalfe DD (1991) The treatment of mastocytosis. J Invest Dermatol 96: 55S-56S
65. Mitsui H, Furitsu T, Dvorak AM, Irani AMA, Schwartz LB, Inagaki N, Takei M, Ishizaka K, Zsebo KM, Gillis S, Ishizaka T (1993) Development of human mast cells from umbilical cord blood cells by recombinant human and murine stem cell factor, c-kit ligand. Proc Natl Acad Sci (USA) 90: 735-740
66. Nagata H, Worobec A, Oh C, Suzuki Y, Metcalfe DD (1995) Identification of a point mutation of the proto-oncogene c-kit in patients with mastocytosis. J All Clin Immunol 95: 176 (abstr)
67. Nettleship E, Tay W (1869) Rare forms of urticaria. Br Med J 2: 323-330
68. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A (1994) Stem cell factor is a chemotactic factor for human mast cells. J Immunol 153: 3717-3724
69. Parker RI (1991) Hematologic aspects of mastocytosis. II. Management of hematologic disorders in association with systemic mast cell disease. J Invest Dermatol 96: 52S-53S
70. Parkin JL, McKenna RW, Brunning RD (1982) Philadelphia chromosome positive blastic leukemia: ultrastructural and ultracytochemical evidence of basophil and mast cell differentiation. Br J Haematol 52: 563-677
71. Parwaresch MR, Horny HP, Lennert K (1985) Tissue mast cells in health and disease. Path Res Pract 179: 439-461
72. Petit A, Pulik M, Gaulier A, Lionnet F, Mahe A, Sigal M (1995) Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alpha therapy. J Am Acad Dermatol 32: 850-853
73. Povoa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG (1991) A case of systemic mastocytosis: therapeutic efficacy of ketotifen. J Intern Med 229: 475-477
74. Prokocimer M, Polliack A (1980) Increased bone marrow mast cells in preleukemic syndromes, acute myeloid leukemias and lympho-proliferative disorders. Am J Clin Pathol 75: 34-38
75. Razin E, Pecht I, Rivera J (1995) Signal transduction events in the activation and growth of mast cells and basophils. Immunol Today 8: 370-374
76. Requena L (1992) Erythrodermic mastocytosis. Cutis 49: 189-192
77. Roberts LJ, Sweetman BJ, Lewis RA, Austen KF, Oates JA (1980) Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 303: 1400-1404
78. Rothenberg ME, Caulfield JP, Austen KF, Hein A, Edmiston K, Newburger PE, Stevens RL (1987) Biochemical and morphological characterization of basophilic leukocytes from two patients with myelogenous leukemia. J Immunol 138: 2616-2625
79. - cell population. Blood 84: 2489-2496
80. Smith ML, Orton PW, Chu H, Weston WL (1990) Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol 7: 251-255
81. Scheck O, Horny HP, Ruck P, Schmelzle R, Kaiserling E (1987) Solitary mastocytoma of the eyelid. Virchows Arch 412: 31-36
82. Schwartz LB, Huff TF (1991) Mast cells. In: Crystal RG, West JB (eds) The lung. Raven Press, New York, pp 601-616
83. Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P (1991) IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 147: 4224-4228
84. Sillaber C, Virgolini I, Li SR, Sperr WR, Agis H, Baghestanian M, Füreder W, Tschachler E, Butterfield JH, Kishi K, Lechner K, Valent P: In vitro and in vivo effects of interferon alpha on human basophils and mast cells (manuscript in preparation)
85. Soler J, O'Brien M, DeCastro JT, Miguel JFS, Kearney L, Goldman JM, Catovsky D (1985) Blast crisis of chronic granulocytic leukemia with mast cell and basophilic precursors. Am J Clin Pathol 83: 254-259
86. Sperr WR, Czerwenka K, Mundigler G, Müller MR, Semper H, Klappacher G, Glogar HD, Lechner K, Valent P (1993) Specific activation of human mast cells by the ligand for c-kit: comparison between lung-, uterus and heart mast cells. Int Arch Allergy Appl Immunol 102: 170-175
87. Stevens J, Loutit JF (1982) Mast cells in spotted mutant mice (W Ph mi). Proc R Soc Lond B 215: 405-409
88. Tachibana M, Perez-Jurado LA, Nakayama A, Hodgkin-son CA, Li X, Schneider M, Miki T, Fex J, Francke U, Arnheiter H (1994) Cloning of MITF, the human homolog of the mouse microphthalmia gene and assignment to chromosome 3p14.1-p12.3. Hum Mol Genet 3: 553-557
89. Travis WD, Li CY, Hogaland HC, Travis LB, Banks PM (1986) Mast cell leukemia: Report of a case and review of the literature. Mayo Clin Proc 61: 957-966
90. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG (1988) Significance of systemic mast cell disease with associated hematologic disorders. Cancer 62: 965-972
91. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-206
92. Valent P (1995) Mast cell differentiation antigens: Expression in normal and malignant cells and use for diagnostic purposes. Eur J Clin Invest 25: 715-720
93. Valent P (1994) The riddle of the mast cell: kit ligand as the missing link? Immunol Today 15: 111-114
94. Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, Bettelheim P (1989) Mast cell typing: demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73: 1778-1785
95. Valent P, Besemer J, Sillaber Ch, Maurer D, Butterfield JH, Kishi K, Lechner K, Bettelheim P (1990) Failure to detect interleukin-3 binding sites on human mast cells. J Immunol 145: 3432-3438
96. Valent P, Bettelheim P (1992) Cell surface structures on human basophils and mast cells: Biochemical and functional characterization. Adv Immunol 52: 333-421
97. Valent P, Bevec D, Maurer D, Besemer J, Butterfield JH, Lechner K, Majdic O, Bettelheim P (1991) Interleukin-4 promotes expression of mast cell ICAM-1 antigen. Proc Natl Acad Sci (USA) 88: 3339-3344
98. Valent P, Sillaber C, Bettelheim P (1991) The growth and differentiation of mast cells. Prog Growth Factor Res 3: 27-41
99. Valent P, Spanblöchl E, Bankl HC, Sperr WR, Marosi C, Pirc-Danoewinata H, Virgolini I, Eichler HG, Agis H, Sillaber C, Bettelheim P, Lechner K (1994) Kit ligand/ mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemia blast crisis. Blood 84: 4322-4332
100. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Agis H, Strobl H, Zsebo KM, Geissler K, Bettelheim P, Lechner K (1992) Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long-term culture. Blood 80: 2237-2245
101. Van-Linthoudt D, Olah AJ, Humair L, Ott H (1994) Isolated bone marrow mastocytosis: a rare cause of osteoporosis not to be missed. Schweiz Rundsch Med Prax 83: 189-192
102. Walsh LJ, Trinchieri G, Waldorf H, Whitaker D, Murphy GF (1991) Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci (USA) 88: 4220-4225
103. Webb TA, Li CY, Yam LT (1982) Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer 49: 927-938
104. Wong KF, Chan JK, Chan JC, Kwong YL, Ma SK, Chow TC (1991) Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol 38: 243-244
105. Yurt RW, Leid RW, Austen KF, Silbert JE (1977) Native heparin from rat peritoneal mast cells. J Biol Chem 252: 518-521
106. Zsebo KM, Williams D, Geissler E, Broudy VC, Martin FH, Actins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV (1990) Stem cell factor (SCF) is encoded at the SI Locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63: 213-220